NGNE vs NKTX

Neurogene Inc. vs Nkarta, Inc. — Valuation Comparison 2026

NGNE

Biotechnology
Neurogene Inc.
Quality
5.2
out of 10
Value Trap
18
SAFE
Price
$27.50
Last close
Models
9/13
Active
VS

NKTX

Biotechnology
Nkarta, Inc.
Quality
4.6
out of 10
Value Trap
18
SAFE
Price
$3.30
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NGNE Fair ValueNGNE Upside NKTX Fair ValueNKTX Upside
Bayesian DCF Intrinsic $11.44 -58.4% $0.66 -80.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $16.56 -39.8% $2.32 -29.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NGNE vs NKTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NGNE vs NKTX — Which Stock Is More Undervalued?

NGNE scores higher with a 5.2/10 quality rating vs NKTX's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Neurogene Inc. (NGNE) and Nkarta, Inc. (NKTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NGNE currently trades at $27.50 with a QOC of 5.2/10, while NKTX trades at $3.30 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).